图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
不入流资讯2023-07-18 17:23
$Karyopharm(KPTI)$ Karyopharm Theraoeutics climbs 25% after securing FDA fast track designation for Selinexor for treatment of Myelofibrosis #AI_Mover#查看全文
药智网2023-08-24 15:20
来源:药智网公众号
图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-007614 Size: 5 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-007610 Size: 5 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-007589 Size: 5 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-007588 Size: 5 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-007583 Size: 5 KB 网页链接
$Karyopharm(KPTI)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001086364-24-003344 Act: 34 Size: 13 KB 网页链接
$Karyopharm(KPTI)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000093751-24-000068 Act: 34 Size: 8 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-003177 Size: 4 KB 网页链接
$Karyopharm(KPTI)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-24-003978 Act: 34 Size: 224 KB 网页链接
$Karyopharm(KPTI)$ 8-K Current report, item 3.01 Accession Number: 0001193125-23-293373 Act: 34 Size: 146 KB 网页链接